Renal Cell Carcinoma (RCC) is the most frequent malignancy encountered in general nephrology practice; when kidney disease develops in the setting of RCC, it may limit long-term outcomes, patients often dying of a non-cancer-related complication of kidney disease.
There is a reciprocal relationship between renal cancer and kidney; chronic kidney disease can increase the risk of developing kidney cancer, and patients with RCC often experience renal impairment owing to pre-existing chronic kidney disease (CKD), hypertension (HTN), diabetes mellitus (DM), and/or other medically challenging comorbidities, or risk factors for CKD. Nephrologists should be involved in all aspects of RCC patients’ care, from pre-nephrectomy evaluation, to management of post-nephrectomy CKD, through the recognition and management of anticancer drugs-related kidney toxicity. This collaborative approach to RCC care will further improve the clinical outcomes of kidney cancer patients.
CapassoABenigniACapitanioU, et al. Summary of the international conference on onco-nephrology: an emerging field in medicine. Kidney Int2019; 96:555–567.
2.
GoASChertowGMFanD, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004; 351:1296–1305.
3.
HungPHTsaiHBHungKY, et al. Increased risk of end-stage renal disease in patients with renal cell carcinoma: a 12-year nationwide follow-up study. Medicine2014; 93:e52.
4.
JeonHGChooSHSungHH, et al. Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. Eur J Cancer2014; 50:64–69.
5.
SunMBeckerATianZ, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol2014; 65:235–241.
6.
Van PoppelHDa PozzoLAlbrechtW, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol2011; 59:543–552.
7.
LowranceWTOrdoñezJUdaltsovaN, et al. CKD and the risk of incident cancer. J Am Soc Nephrol2014; 25:2327–2334.
8.
DentonMDMageeCCOvuworieC, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int2002; 61:2201–2209.
9.
StewartJHBucciantiGAgodoaL, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol2003; 14:197–207.
10.
WengPHHungKYHuangHL, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol2011; 6:1121–1128.
11.
ChenCYLiaoYMTsaiWM, et al. Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. J Formos Med Assoc2007; 106:992–998.
12.
JørgensenLHeuchIJenssenT, et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol2008; 19:992–998.
13.
HartmannAJenssenTHoldaasH.Diabetes, chronic kidney disease and cancer risk. Nephrol Dial Transplant2012; 27:3018–3020.
14.
BengtssonUJohanssonSAngervallL.Malignancies of the urinary tract and their relation to analgesic abuse. Kidney Int1978; 13:107–113.
15.
NortierJLMartinezMCSchmeiserHH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med2000; 342:1686–1692.
16.
PerazellaMADreicerRRosnerMH.Renal cell carcinoma for the nephrologist. Kidney Int2018; 94:471–483.
17.
KimSHLeeSEHongSK, et al. Incidence and risk factors of chronic kidney disease in Korean patients with t1a renal cell carcinoma before and after radical or partial nephrectomy. Jpn J Clin Oncol2013; 43:1243–1248.
18.
CanterDKutikovASirohiM, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology2011; 77:781–785.
19.
BarlowLJKoretsRLaudanoM, et al. Predicting renal functional outcomes after surgery for renal cortical tumours: a multifactorial analysis. BJU Int2010; 106:489–492.
20.
JeonHGJeongIGLeeJW, et al. Prognostic factors for chronic kidney disease after curative surgery in patients with small renal tumors. Urology2009; 74:1064–1068.
21.
ClarkMAShikanovSRamanJD, et al. Chronic kidney disease before and after partial nephrectomy. J Urol2011; 185:43–48.
22.
ChoiYSParkYHKimYJ, et al. Predictive factors for the development of chronic renal insufficiency after renal surgery: a multicenter study. Int Urol Nephrol2014; 46:681–686.
23.
TakagiTKondoTIizukaJ, et al. Postoperative renal function after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease: a comparison with radical nephrectomy. Internet J Urol2011; 18:472–476.
24.
LiLLauWLRheeCM, et al. Risk of chronic kidney disease after cancer nephrectomy. Nat Rev Nephrol2014; 10:135–145.
25.
MalcolmJBBagrodiaADerweeshIH, et al. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU Int2009; 104:476–481.
26.
StilesKPMoffattMJAgodoaLY, et al. Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival. Kidney Int2003; 64:247–253.
27.
ChoALeeJEKwonGY, et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant2011; 26:3496–3501.
28.
ChristiansenCFJohansenMBLangebergWJ, et al. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med2011; 22:399–406.
29.
LamAQHumphreysBD.Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol2012; 7:1692–1700.
30.
SongCBangJKParkHK, et al. Factors influencing renal function reduction after partial nephrectomy. J Urol2009; 181(1): 48–53; discussion 53–54.
31.
HenriksenKJMeehanSMChangA.Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med2009; 133:1012–1025.
32.
PerazellaMARosnerMH.Acute kidney injury in patients with cancer. Oncology2018; 32:351–359.
33.
ThadhaniRPascualMBonventreJV.Acute renal failure. N Engl J Med1996; 334:1448–1460.
34.
BachrachLNegronELiuJS, et al. Preoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology2014; 84(6): 1402–1406.
35.
SankinASfakianosJPSchiffJ, et al. Assessing renal function after partial nephrectomy using renal nuclear scintigraphy and estimated glomerular filtration rate. Urology2012; 80:343–346.
36.
YouSHSungDJYangKS, et al. Predicting the development of surgically induced chronic kidney disease after total nephrectomy using body surface area–adjusted renal cortical volume on CT angiography. AJR Am J Roentgenol2019; 212:W32–W40.
37.
ScosyrevEMessingEMSylvesterR, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol2014; 65:372–377.
38.
HuSLChangAPerazellaMA, et al. The nephrologist’s tumor: basic biology and management of renal cell carcinoma. J Am Soc Nephrol2016; 27:2227–2237.
39.
KimSPThompsonRHBoorjianSA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol2012; 188:51–57.
40.
YanikELClarkeCASnyderJJ, et al. Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals. J Am Soc Nephrol2016; 27(5): 1495–1504.
41.
WeightCJLarsonBTFerganyAF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol2010; 183:1317–1323.
42.
YapSAFinelliAUrbachDR, et al. Partial nephrectomy for the treatment of renal cell carcinoma (RCC) and the risk of end-stage renal disease (ESRD). BJU Int2015; 115:897–906.
43.
LaneBRCampbellSCDemirjianS, et al. Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. J Urol2013; 189:1649–1655.
44.
CapitanioULarcherACianfloneF, et al. Hypertension and cardiovascular morbidity following surgery for kidney cancer. Eur Urol Oncol2020; 3:209–215.
45.
Van PoppelHSylvesterR. Is overall survival not influenced by partial vs radical nephrectomy?BJU Int2018; 121(3): 319–319.
46.
ShuchBHanleyJLaiJ, et al. Overall survival advantage with partial nephrectomy: a bias of observational data?Cancer2013; 119:2981–2989.
47.
WolduSLWeinbergACKoretsR, et al. Who really benefits from nephron-sparing surgery?Urology2014; 84:860–867.
48.
LarcherACapitanioUTerroneC, et al. Elective nephron sparing surgery decreases other cause mortality relative to radical nephrectomy only in specific subgroups of patients with renal cell carcinoma. J Urol2016; 196:1008–1013.
49.
ChanVWAbulAOsmanFH, et al. Ablative therapies versus partial nephrectomy for small renal masses - a systematic review and meta-analysis. Internet J Surg2022; 97:106194.
50.
OlwenyEOParkSKTanYK, et al. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol2012; 61:1156–1161.
51.
CosmaiLPortaCGallieniM.Onco-nephrology: a decalogue. Nephrol Dial Transplant2016; 31:515–519.
52.
MarconiLDesaiMMFicarraV, et al. Renal preservation and partial nephrectomy: patient and surgical factors. Eur Urol Focus2016; 2:589–600.
53.
PortaCBamiasADaneshFR, et al. KDIGO controversies conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int2020; 98:1108–1119.
54.
TrevisaniFGhidiniMLarcherA, et al. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. Br J Cancer2016; 115:1343–1350.
55.
ZacchiaMVilasiACapassoA, et al. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol2011; 24:155–164.
56.
CapitanioULarcherAKriegmairMC, et al. Do we truly care about the functional outcomes for renal cancer patients? Multidisciplinarity is still far away. Eur Urol2019; 75:349–350.
57.
European Association of Urology. Renal Cell Cancer Guidelines, 2020.
58.
CampbellSCUzzoRGKaramJA, et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol2021; 206:209–218.
59.
FinelliAIsmailaNRussoP.Management of small renal masses: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract2017; 13:276–278.
60.
CaninoCPerroneLBoscoE, et al. Targeting angiogenesis in metastatic renal cell carcinoma. Expert Rev Anticancer Ther2019; 19:245–257.
61.
PortaCPaglinoCImarisioI, et al. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Sci World J2007; 7:837–849.
62.
HasanovEGaoJTannirNM.The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results. Cancer J2020; 26:419–431.
63.
IzzedineHEl-FekihRKPerazellaMA.The renal effects of ALK inhibitors. Investig New Drugs2016; 34:643–649.
64.
GonzálezEGutiérrezEGaleanoC, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int2008; 73:940–946.
65.
MuriithiAKLeungNValeriAM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis2014; 64:558–566.
66.
MarcoTAnnaPAnnalisaT, et al. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Ther Adv Med Oncol2019; 11:1758835919875549.
67.
RosnerMHJhaveriKDMcMahonBA, et al. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin2021; 71:47–77.
68.
PerazellaMAShiraliAC.Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?Kidney Int2020; 97:62–74.
69.
CortazarFKibbelaarZAGlezermanIG, et al. Clinical features and out-comes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol2020; 31:435–446.
70.
CassolCSatoskarALozanskiG, et al. Anti−PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep2019; 4:1152–1160.
71.
SeethapathyHZhaoSChuteDF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol2019; 14:1692–1700.
72.
ZhuXWuSDahutWL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis2007; 49:186–193.
73.
EstradaCCMaldonadoAMallipattuSK.Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol2019; 30:187–200.
74.
PortaCCosmaiLGallieniM, et al. Renal effects of targeted anticancer therapies. Nat Rev Nephrol2015; 11:354–370.
75.
AliABhanCMalikMB, et al. The prevention and management of contrast-induced acute kidney injury: a mini-review of the literature. Cureus2018; 10:e3284.
76.
JuwonLJangGKimS, et al. Outcomes of acute kidney injury patients with and without cancer. Ren Fail2015; 37:332–337.
77.
SalahudeenAKDoshiSMPawarT, et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol2013; 8:347–354.
78.
PirovanoMMineiSRe SartòGV, et al. Risk of acute kidney injury in cancer patients after iodinated contrast medium administration and prophylactic strategies: summary from the most recent guidelines. J Onco-Nephrol2021; 5:114–119.
79.
BednarekAMykała-CieślaJPogodaK, et al. Limitations of systemic oncological therapy in breast cancer patients with chronic kidney disease. J Oncol2020; 2020:7267083.
80.
van der MolenAJReimerPDekkersIA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol2018; 28:2856–2869.
81.
American College of Radiology. Committee on drugs and contrast media. ACR Manual on Contrast Media, 2020,
82.
PullenLC.Cancer and transplant: a delicate balance. Am J Transplant2021; 21:443–444.
83.
BijolVBatalI.Non-neoplastic pathology in tumor nephrectomy specimens. Surg Pathol Clin2014; 7:291–305.
84.
SalvatoreSPChaEKRosoffJS, et al. Non-neoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function. Arch Pathol Lab Med2013; 137:531–540.
85.
HenriksenKJMeehanSMChangA.Non-neoplastic renal diseases are often unrecognized in adult tumor nephrectomy specimens: a review of 246 cases. Am J Surg Pathol2007; 31:1703–1708.
86.
SrigleyJRAminMBDelahuntB, et al. Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. Arch Pathol Lab Med2010; 134:e25–e30.
AlgabaFDelahuntBBerneyDM, et al. Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European network of uropathology. J Clin Pathol2012; 65:106–113.
